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Abstract
Introduction: Vitamin E is beneficial in restoring bone histomorphometric
parameters in nicotine-treated rats. This study determined the effectiveness of
3 forms of vitamin E in restoring bone metabolism in nicotine-treated rats.
Material and methods: Thirty-five male Sprague-Dawley rats were divided into
5 groups: (1) control (C), (2) nicotine cessation (NC), (3) α-tocopherol (ATF), (4)
tocotrienol-enhanced fraction (TEF) and (5) γ-tocotrienol (GTT). Treatment was
carried out for 4 months. The control group was administered normal saline and
olive oil throughout the treatment period while treatment for groups 2-5 was
performed in 2 phases. In the first phase, the groups received nicotine 7 mg/kg
intraperitoneally for 2 months. The following 2 months, group 2 received normal
saline and olive oil while groups 3-5 received ATF, TEF or GTT, 60 mg/kg orally.
Pre-treatment and post-treatment serum was collected for bone biochemical
marker measurement using the ELISA method.
Results: Nicotine increased serum bone-resorbing cytokines (interleukin-1 and
interleukin-6) and the bone resorption marker pyridinoline (PYD) while reducing
the bone formation marker osteocalcin after 2 months of nicotine treatment.
The parameters failed to improve after nicotine was stopped for 2 months.
Supplementation with the 3 forms of vitamin E improved the parameters, i.e.
reduced the cytokines and pyridinoline as well as increased the osteocalcin. In
addition, the TEF and GTT groups had a higher level of osteocalcin than the
control group.
Conclusions: Nicotine impaired bone metabolism and cessation of nicotine
treatment did not reverse the effects. Vitamin E, especially the tocotrienols,
restored bone metabolism that was impaired due to nicotine.
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Introduction
Bone remodelling is a continuous process whereby bone is resorbed by
osteoclasts and the new bone is replaced by bone-forming cells, i.e.
osteoblasts. [1]. Bone turnover is regulated by many factors such as
mechanical forces, hormones (parathyroid and growth hormones),
cytokines and local factors [2]. The cytokines, such as interleukins, receptor
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activator of nuclear factor κB ligand (RANKL), tumour
necrosis factor-α (TNF-α), interferons and trans  -
forming growth factor-β (TGF-β), affect bone
metabolism by regulating the function of osteoblasts
and osteoclasts. For instance, interleukin-1 and
interleukin-6 (IL-1 and IL-6) increase osteoclast
generation, RANKL inhibits apoptosis of osteoclasts,
while TNF-α inhibits osteoblasts [2]. 
The production of cytokines mentioned above
can be influenced by free radicals. A pathological
condition such as ovariectomy causes accumulation
of reactive oxygen species which in turn promotes
the production of TNF-α [3]. In another study,
oxidative stress promotes the production of TGF-β
and osteopontin, which are associated with bone
resorption [4]. Thus, bone remodelling is very much
dependent on a balance between oxidants and
antioxidants. Overwhelming levels of free radicals
will disrupt the balance between bone formation
and resorption and will lead to bone loss, and hence
osteoporosis [5]. 
Oxidative stress can be induced by many
substances, one of which is nicotine [6]. Nicotine
has been shown to increase the production of
inflammatory mediators [7] and nicotine has been
associated with pathogenesis of diseases by
promoting proinflammatory mediators [8]. On bone,
nicotine induced bone loss and reduced bone
mechanical strength in rats [9]. In humans, smoking
has been implicated in osteoporosis [10] and is
considered one of the risk factors for osteoporosis
[11]. Exposure to nicotine has been associated with
low bone mineral content in both males and
females [12]. In our previous study, we observed
that nicotine increased IL-1 and IL-6 [13], and
increased pyridinoline but reduced osteocalcin levels
significantly [14]. 
Nicotine-induced osteoporosis may be prevented
if the effects of nicotine on promoting oxidative
stress can be overcome. This may be made possible
by using antioxidants. These antioxidants may act
by preventing oxidative stress and curb the
overproduction and overactivity of inflammatory
mediators such as the interleukins. One of the
antioxidants is vitamin E, which exists in 2 forms,
i.e. tocopherol and tocotrienol, with 4 isomers each.
Vitamin E has been shown to possess antioxidant
activities and the activities vary among the different
isomers [15]. It suppresses the activation of the
inflammatory cascade induced by alcohol [16],
reduces the production of IL-6 by macrophages [17]
and may play a role in preventing osteoporosis [18].
Vitamin E has also been shown to improve the
biomarkers of bone metabolism in rats treated with
ferric nitrilotriacetate [19]. Palm oil is one of the
natural sources of vitamin E and predominantly
contains the tocotrienol type of vitamin E. 
A previous study has shown that palm vitamin E,
which is mainly composed of tocotrienols, is
superior to α-tocopherol in protecting bone [20]. 
Based on the above findings, it is postulated that
vitamin E may play a role as a therapeutic agent in
preventing bone loss in nicotine-exposed subjects.
This study was carried out to determine the effects
of vitamin E on the bone of rats exposed to nicotine
toxicity. We hypothesized that vitamin E may be able
to prevent the adverse effects of nicotine by
preventing the overproduction of bone-resorbing
cytokines. In this study, a comparison was made
between 3 types of vitamin E preparations, 
1) α-tocopherol, 2) tocotrienol-enhanced fraction (TEF
– a mixture of tocotrienols) and 3) γ-tocotrienol, to
investigate which preparations affect bone the most
since different isomers or different pre  parations of
vitamin E might affect a body system differently. 
Material and methods
Animals and treatment
Thirty-five 3-month old Sprague-Dawley male
rats were obtained from the Laboratory Animal
Resource Unit, Universiti Kebangsaan Malaysia. The
rats were then randomly assigned to 5 groups of 
7 rats each and treated for 4 months: (1) control
group which received vehicle normal saline and
vehicle olive oil (C), (2) nicotine cessation group
which received nicotine 7 mg/kg and vehicle olive
oil for the first 2 months followed by vehicle olive
oil and vehicle normal saline administration for the
following 2 months (NC), (3) α-tocopherol group
(ATF), (4) tocotrienol-enhanced fraction group (TEF)
and (5) γ-tocotrienol group (GTT). Groups 3-5
received the same nicotine treatment as in group 2
for the first 2 months, but for the following 
2 months, the groups received vehicle normal saline
and either α-tocopherol, tocotrienol-enhanced
fraction or γ-tocotrienol in the dose of 60 mg/kg
respectively.
The rats were housed 3 per cage under 12-h
natural light/dark cycles and given tap water ad
libitum. All rats received normal rat chow obtained
from Gold Coin (Port Klang, Selangor, Malaysia). The
nicotine used was nicotine hydrogen tartrate salt
which was purchased from Sigma Chemical Co. 
(St Louis, MO, USA). α-Tocopherol acetate was
purchased from Sigma Chemical Co. (St Louis, MO,
USA) while the Malaysian Palm Oil Board (Bangi,
Selangor, Malaysia) supplied the tocotrienol-
enhanced mixture. The tocotrienol-enhanced
mixture was made up of 42.98% α-tocotrienol,
30.98%  γ-tocotrienol, 13.81% δ-tocotrienol and
12.23% palm oil devoid of α-tocopherol. 
γ-Tocotrienol was a gift from Carotech Berhad
(Chemor, Perak, Malaysia). Blood samples were
taken before the start of treatment, after 2 months
of treatment and at the end of the treatment period.Arch Med Sci 4, August / 2010 507
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Nicotine 7 mg/kg was prepared by mixing 0.07 g
of nicotine in 10 ml of normal saline. The vitamin E
solutions were prepared by mixing 3 g of the
respective vitamin Es in 50 ml of olive oil (Bertolli,
Secaucus, NJ, USA) to get the dose of 60 mg/kg. 
A total of 0.1 ml/100 g rat weight of the nicotine
and vitamin E preparations were respectively given
intraperitoneally and orally via oral gavage, 6 days
a week. The nicotine and vitamin E dosages used
in this study have been documented earlier to be
effective in causing changes in bone metabolism
based on our previous studies [21, 22].
Bone biochemical markers
Serum IL-1α and IL-6 were measured by using
rat ELISA kits (Bender MedSystems, Vienna,
Austria). Serum osteocalcin was determined by
using an ELISA kit purchased from Nordic Bioscience
Diagnostic A/S (Herlev, Denmark). Serum pyri  -
dinoline was measured by using the METRA EIA kit
from Quidel Co. (San Diego, USA).
Serum cotinine levels
Cotinine, which is a metabolite of nicotine, was
measured in the serum using an ELISA kit (DRG
Instruments, Germany). 
Statistical analysis
Data analyses were performed by using
‘Statistical Package for Social Sciences’ (SPSS 12.0).
The data were tested for normality using the
Kolmogorov-Smirnov test and were found to be
normally distributed. The data were analysed by
using one-way analysis of variance (ANOVA)
followed by Tukey’s HSD as the post-hoc test.
Results were presented as mean ± standard error
of the mean (SEM).
The work was conducted in accordance with 
the Universiti Kebangsaan Malaysia Animal 
Ethics Committee with the approval number
FAR/2003/IMA/12JUNE/095.
Results
Table I shows the results of all parameters, i.e.
serum levels of IL-1, IL-6, osteocalcin and pyri  -
dinoline after 2 months’ treatment with nicotine.
Interleukin-6 was increased in the NC group at
month 2 compared to month 0. IL-6 was also
increased in the TEF group after the 2nd month of
nicotine treatment compared to controls. Serum 
IL-1 was significantly increased after nicotine
treatment in all the groups compared to the control
group. A similar pattern could be seen in the PYD
results. The levels were increased in the treatment
groups at month 2 as compared to the control
group and also as compared to month 0 within the
same groups. Osteocalcin levels were reduced in 
all treatment groups at month 2 as compared to
month 0. Serum levels of cotinine were also
measured and the values increased significantly in
NC, ATF, TEF and GTT groups at month 2 as
compared to month 0 and differed significantly
compared to the control group.
Upon giving TEF or GTT, both IL-1 (Figure 1) and
IL-6 (Figure 2) levels were significantly decreased
back to normal level. α-Tocopherol supplementation
was also able to reduce IL-1 levels back to normal
value but failed to cause the same effect on IL-6.
In addition, IL-1 levels were still high even though
nicotine treatment was stopped for 2 months (NC
group at month 4).
Group IL-1 [pg/ml] IL-6 [pg/ml]O steocalcin [ng/ml]P yridinoline [nmol/l] Cotinine [ng/ml]
Month 0 Month 2 Month 0 Month 2 Month 0 Month 2 Month 0 Month 2 Month 0 Month 2
C 316.57 307.41 731.30 716.34 195.22 163.34 2.47 3.71 3.0 4.0
±49.16 ±15.36 ±153.84 ±116.68  ±31.59 ±9.94 ±0.24 ±0.45 ±0.3 ±0.3
NC 198.06 566.83 262.12 456.07 287.29 119.43 2.96 5.45 2.9 56.0
±18.45 ±27.67*# ±13.24# ±65.62* ±8.28 ±15.96*# ±0.49 ±0.23*# ±0.5 ±3.0*#
ATF 267.36 598.17 513.76 704.69 214.56 120.53 2.10 6.65 3.2 54.0
±58.81 ±43.92*# ±110.83 ±140.82 ±21.21 ±9.12*# ±0.13 ±0.42*# ±0.3 ±3.0*#
TEF 300.54 693.46 703.39 1052.84 237.24 118.04 2.67 6.34 2.9 54.7
±56.84 ±104.08*# ±133.80 ±111.78# ±31.97 ±10.25*# ±0.38 ±0.34*# ±0.5 ±3.0*#
GTT 304.10   624.50 502.77 901.24   237.24 118.04 2.51 6.25 3.3 55
±74.00 ±77.29*# ±91.15 ±114.52 ±31.97 ±10.25*# ±0.13 ±0.22*# ±0.5 ±3.0*#
Table I. Serum levels of bone biomarkers and cotinine in all groups after 2 months of nicotine administration
C – control group supplemented with vehicles i.e. olive oil and normal saline, NC – rats treated with nicotine 7 mg/kg and olive oil for 2 months
and followed by olive oil and normal saline for another 2 months, ATF – rats treated with nicotine 7 mg/kg and olive oil for 2 months and followed
by α-tocopherol 60 mg/kg and normal saline for another 2 months, TEF – rats treated with nicotine 7 mg/kg and olive oil for 2 months and
followed by tocotrienol-enhanced fraction 60 mg/kg and normal saline for another 2 months, GTT – rats treated with nicotine 7 mg/kg and olive
oil for 2 months and followed by  γ-tocotrienol 60 mg/kg and normal saline for another 2 months, *indicates significant difference compared to
month 0 (p < 0.05), #indicates significant difference compared to control group of the respective month (p < 0.05)508 Arch Med Sci 4, August / 2010
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The same can be said for PYD levels (Figure 3).
The values were persistently high in the NC group
even though nicotine treatment was stopped at
month 4. On the other hand, at month 4,
supplementation of ATF, TEF and GTT significantly
reduced PYD levels when compared to month 2.
Furthermore, PYD levels in the TEF and GTT groups
were significantly lower than the NC group at
month 4. The ATF group did not share this effect. 
After 2 months of ATF, TEF and GTT sup  -
plementations, i.e. month 4, osteocalcin levels were
significantly increased compared to month 2 within
the same groups (Figure 4). In addition, osteocalcin
levels for TEF and GTT groups at month 4 were
significantly higher than the NC group and were
even higher than the control group. α-Tocopherol
did not differ significantly from the NC group or the
control group as seen in TEF and GTT groups. 
During the second phase of the study, nicotine
administration was terminated and cotinine levels
reduced in all treatment groups as seen at month 4
(Figure 5).
Discussion
Nicotine has been shown to induce oxidative
stress [23] and oxidative stress has been shown to
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Figure 1. The effects of vitamin E supplementation
on IL-1 levels after 2 months nicotine cessation
*indicates significant difference compared to month 2
(p < 0.05), #indicates significant difference compared to
control group of the respective month (p < 0.05), aindicates
significant difference compared to NC group (p < 0.05)
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Figure 2. The effects of vitamin E supplementation
on IL-6 after 2 months nicotine cessation 
*indicates significant difference compared to month 2 
(p < 0.05), #indicates significant difference compared to
control group of the respective month (p < 0.05), aindicates
significant difference compared to NC group (p < 0.05)
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Figure 3. The effects of vitamin E supplementation
on pyridinoline levels after 2 months nicotine
cessation
*indicates significant difference compared to month 2 
(p < 0.05), #indicates significant difference compared to
control group of the respective month (p < 0.05), aindicates
significant difference compared to NC group (p < 0.05)
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Figure 4. The effects of vitamin E supplementation
on osteocalcin levels after 2 months nicotine
cessation 
*indicates significant difference compared to month 2 
(p < 0.05), #indicates significant difference compared to
control group of the respective month (p < 0.05), aindicates
significant difference compared to NC group (p < 0.05)
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cause bone loss [4]. As a sign of oxidative stress,
organs or tissues produce and overexpress
inflammatory mediators such as IL-1 and IL-6, as
depicted in an earlier study on hepatocytes exposed
to ethanol [24].
In the present study, nicotine administration
caused an increase in IL-1. Since IL-1 is one of the
bone-resorbing cytokines, the increase in this
parameter is suggestive of increased bone
resorption. Similar findings were observed by Kamer
et al. [25], who observed that nicotine induced
cytokine release in osteoblast cells. Zhang et al. [26]
observed that cigarette smoke increased both IL-1
and IL-6 levels. 
Even though in this study we have observed
deleterious effects of nicotine on bone parameters,
others have found differently. Nicotine administered
subcutaneously for 12 weeks did not affect bone
mineral density [27], while nicotine given in drinking
water for 4 months reduced bone mineral density
and affected the mechanical properties of bone [9].
The differences between past studies and ours
might be attributed to different dosages and
different route of administration.
The rats in this study received nicotine via
intraperitoneal injection. In order to ensure that the
nicotine injected reached the systemic circulation,
we measured the serum levels of cotinine, 
a metabolite of nicotine. It was found that the
cotinine level for the NC group was 56 ng/ml after
2 months of nicotine administration. An earlier
study in humans showed that the serum cotinine
level in individuals who smoke 10 to 20 cigarettes
per day was 61.59 ng/ml [28]. We also found low
cotinine levels at pre-treatment and at completion
of the study in all groups, which might be due to
environmental tobacco smoke (ETS).
Interleukin-1 and IL-6 were found to disturb the
enzymatic antioxidant defences, which may lead to
oxidative stress [29]. Bone loss due to oxidative
stress may be prevented by the administration of
antioxidants [30]. In this study, IL-1 was increased
due to nicotine treatment and vitamin E sup  -
plementation was found to be able to reverse 
these effects. In comparing between the various
vitamin E preparations, all 3 preparations showed
similar ability in reversing the nicotine-induced
increase in IL-1. This differs from our previous study
in which palm tocotrienol mixture was superior to
α-tocopherol in reversing the increase of IL-1 and
IL-6 levels in nicotine-treated [31] and ferric-
nitrilotriacetate-treated rats [32]. 
The serum levels of IL-6 showed inconsistencies.
The values were higher in the control group from
the beginning of the study. Nicotine treatment (NC
group) did not cause an increase in IL-6 levels as
compared to the control group. The measurement
of IL-6 as an indicator of inflammation is less
reliable than other inflammatory markers [33].
Furthermore, a study on biological variation of IL-6
showed it to have high between-subject coefficient
variation, high within-subject coefficient variation,
a high individuality index and a low reliability
coefficient [34]. This might be the reason for the
inconsistent values of IL-6 seen in this study.
The role of other cytokines must also be
considered. Besides interleukins, tumour necrosis
factor is another pro-inflammatory cytokine that is
involved in stimulating bone resorption [35], and its
measurement may be more meaningful. In addition,
bone is also maintained by growth factors such as
transforming growth factor, which helps in the
balance between bone resorption and formation
[36]. It was found that whilst IL-1 increases bone
resorption, transforming growth factor reduces
bone resorption [37]. These factors may contribute
to the variations in IL-6 findings in this study. 
Vitamin E may exert its effects on bone cytokines
via its antioxidant properties. In our previous study,
we found that palm tocotrienol mixture was able
to reduce lipid peroxidation and increase
glutathione peroxidase activity in the femur of
normal rats [20]. In other studies, vitamin E has
been reported to possess anti-inflammatory
activities [38] by suppressing proinflammatory
markers [39]. In addition, the immunoregulatory
functions of vitamin E during inflammation differ
with different vitamin E isomers, as has been
shown earlier with tocopherol isomers [40]. 
The increase of cytokines such as IL-1 and IL-6
is associated with osteoclastic bone resorption [41].
In this study, we observed an increase of IL-1 when
nicotine was administered and the findings
corresponded with the increase in the bone
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resorption marker PYD. Similarly, vitamin E
supplementation also reversed the increase in PYD.
However, the PYD levels in the ATF group were
comparable to the NC group, unlike TEF and GTT,
which demonstrated significantly lower PYD values
than the NC group. This suggests a lower efficacy
of ATF. Our previous study showed that vitamin E
was able to reduce levels of the bone-resorbing
marker deoxypyridinoline (DPD) in nicotine-induced
rats [31]. In rats treated with ferric nitrilotriacetate,
palm tocotrienol mixture was better than 
α-tocopherol in reducing the bone resorption
marker [32].  
The present study also showed that nicotine
reduced the levels of osteocalcin (bone formation
marker) while vitamin E supplementation was able
to revert the levels back to normal. The tocotrienol
treated groups (TEF and GTT) had even higher
osteocalcin values than the control group. This is
suggestive of anabolic actions of vitamin E on bone
and requires further study. α-Tocopherol did not
seem to exert this effect. 
Previous studies have shown conflicting results
as far as osteocalcin levels are concerned. In one
study, administration of α-tocopherol acetate to
mice increased the synthesis of femoral bone
protein as shown by an increase in osteocalcin
mRNA [42]. In our previous studies, supple  -
mentation of vitamin E in rats treated with ferric
nitrilotriacetate [32] and in rats treated with
nicotine [31] did not cause any significant changes
in osteocalcin levels. The different outcome
observed between this study and our previous
studies may be due to the different study design
applied. In this study, vitamin E supplementation
was given after the oxidant (nicotine) was stopped,
while in the previous studies, vitamin E supple  -
mentation was given concurrently with the oxidants
(ferric nitrilotriacetate and nicotine). This suggests
that the antioxidant effect of vitamin E is more
evident when the source of oxidant is stopped.
The findings of this study are in accordance with
our previous study with regards to bone
histomorphometric analysis. Our previous study
reported that rats administered nicotine followed
by vitamin E supplementation showed an
improvement in structural, dynamic and cellular
bone histomorphometric parameters as compared
to unsupplemented rats [43]. The superiority of
tocotrienol-supplemented groups observed in this
study was also observed in the previous study, in
which supplementation of tocotrienol showed
superior effects on bone histomorphometric
parameters compared to α-tocopherol [43].
γ-Tocotrienol is shown to be the more potent
isomer in reducing serum lipid parameters [44] and
in inhibiting adipogenesis [45]. However, in this
study, TEF and GTT exert comparable effects on 
all the parameters measured, indicating that 
a tocotrienol mixture is just as good as the pure 
γ-tocotrienol. In contrast, GTT has been shown
previously to exert better effects than TEF on bone
histomorphometric parameters in nicotine-induced
rats [43].
In this study, the rats were administered nicotine
for 2 months and were kept for another 2 months
without nicotine treatment. We observed that the
pathological processes induced by nicotine on the
bone biochemical markers were not reversed when
nicotine administration was stopped (as seen in
group NC for all parameters). This further confirms
that nicotine cessation alone is not sufficient to
reverse the adverse effects of nicotine on bone.
Vitamin E supplementation may be beneficial in
restoring bone homeostasis back to normal.
In conclusion, nicotine treatment for 2 months
impaired bone metabolism, which was not reversed
following a 2-month nicotine-free period. Vitamin E
supplementation (ATF, TEF and GTT) was able to
reverse the effects of nicotine on bone metabolism,
most probably due to its immunoregulatory effects.
However, different types and isomers of vitamin E
may exert different effects on the inflammatory
mediators as the tocotrienols were found to be
superior to α-tocopherol in reversing the effects of
nicotine. 
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